- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: Lethargy.
Displaying page 1 of 2.
EudraCT Number: 2020-003366-39 | Sponsor Protocol Number: APHP200702 | Start Date*: 2020-10-16 |
Sponsor Name:Assitance Publique-Hopiaux de Paris | ||
Full Title: CAMOVID: A multicenter randomized trial to evaluate the efficacy and safety of camostat mesylate for the treatment of SARS-CoV-2 infection in ambulatory adult patients. | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003136-23 | Sponsor Protocol Number: CRO1990 | Start Date*: 2012-11-27 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||||||||||||||||||||||
Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness | ||||||||||||||||||||||||||||||||||||||
Medical condition: Borderline Personality Disorder | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000502-40 | Sponsor Protocol Number: RHM CAN0380 | Start Date*: 2005-05-13 |
Sponsor Name:Southampton University Hospitals Trust | ||
Full Title: A thematic analysis of semi-structured interviews using a phenomenological approach into palliative care patients experiences of change in "fatigue" following treatment with methylphenidate – an ex... | ||
Medical condition: Patients with cancer in palliative stage of their illness. Suffering from fatigue with or without decreased concentration, depression or drowsiness, who feel their fatigue is severe enough to decre... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005452-41 | Sponsor Protocol Number: DPM-B-301 | Start Date*: 2006-05-26 |
Sponsor Name:Pharmaxis UK Limited | ||
Full Title: A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic tr... | ||
Medical condition: Bronchiectasis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000680-22 | Sponsor Protocol Number: SAG-37/DIV | Start Date*: 2007-10-29 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurre... | |||||||||||||
Medical condition: Diverticultits | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) NL (Completed) LV (Completed) LT (Completed) SK (Completed) EE (Completed) GB (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003718-10 | Sponsor Protocol Number: 2014RISP-ID01 | Start Date*: 2015-09-15 |
Sponsor Name:UMCG | ||
Full Title: A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability | ||
Medical condition: no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015158-39 | Sponsor Protocol Number: SAG-51/DIV | Start Date*: 2010-05-06 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, dose-response, randomised, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevent... | |||||||||||||
Medical condition: Diverticulitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003252-24 | Sponsor Protocol Number: 53718678RSV2004 | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Le... | |||||||||||||
Medical condition: Respiratory Syncytial Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) SE (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000936-17 | Sponsor Protocol Number: GWEP1560 | Start Date*: 2019-07-23 | ||||||||||||||||
Sponsor Name:GW Research Ltd | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of GWP42003-P in Conjunction with Hypothermia in Neonates with ... | ||||||||||||||||||
Medical condition: Neonatal Hypoxic-Ischemic Encephalopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013667-19 | Sponsor Protocol Number: CAFQ056A2212 | Start Date*: 2010-11-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019962-10 | Sponsor Protocol Number: P1-SAF301 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:SANFILIPPO Therapeutics SAS | |||||||||||||
Full Title: AN OPEN-LABEL, SINGLE ARM, MONOCENTRIC, PHASE I/II CLINICAL STUDY OF INTRACEREBRAL ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS SEROTYPE 10 CARRYING THE HUMAN SGSH AND SUMF1 cDNAS FOR THE TREAT... | |||||||||||||
Medical condition: Sanfilippo type A syndrome (also named Mucopolysaccharidosis Type A) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008141-37 | Sponsor Protocol Number: diab123v1.0 | Start Date*: 2009-09-08 | ||||||||||||||||
Sponsor Name:Sherwood Forest Hospitals Foundation Trust | ||||||||||||||||||
Full Title: Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study | ||||||||||||||||||
Medical condition: sleepiness and lethargy among obese patients with diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001382-10 | Sponsor Protocol Number: CS/2015/4775 | Start Date*: 2019-01-21 | |||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | |||||||||||||
Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service | |||||||||||||
Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002836-97 | Sponsor Protocol Number: 240193 | Start Date*: 2012-12-20 |
Sponsor Name:Tartu University Hospital | ||
Full Title: Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates | ||
Medical condition: neonatal sepsis, pneumonia and meningitis | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003243-34 | Sponsor Protocol Number: C2661002/D3720C00009 | Start Date*: 2015-02-02 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis | |||||||||||||
Medical condition: Late-onset Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) IT (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002997-35 | Sponsor Protocol Number: OVG2014/05 | Start Date*: 2015-02-06 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A phase III multi-centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis (The IgNiTE study) | |||||||||||||
Medical condition: Encephalitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006059-13 | Sponsor Protocol Number: Tacho01 | Start Date*: 2012-04-16 | |||||||||||
Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA | |||||||||||||
Full Title: The use of Tachosil as sealant in the prevention of lymphorrea after groin lymphadenectomy for vulvar cancer: a clinical controlled prospective trial | |||||||||||||
Medical condition: lymphedema after groin lymphadenectomy in patients with vulvar cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004150-32 | Sponsor Protocol Number: A8851008 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Pfizer, Spain | |||||||||||||
Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM... | |||||||||||||
Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001862-56 | Sponsor Protocol Number: 64041575RSV2004 | Start Date*: 2018-01-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (... | |||||||||||||
Medical condition: Respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002645-11 | Sponsor Protocol Number: SPP1C302 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:SBI Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: An Open-label, Randomized Study to Evaluate Safety, Tolerability and Pharmacokinetics of 5-ALA/SFC in Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia. | |||||||||||||
Medical condition: Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
